Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Novel Drug Blocks Activity of Toxic Alzheimer's Disease Peptides

By BiotechDaily International staff writers
Posted on 19 Dec 2013
Image: Micrograph of an adult Caenorhabditis elegans (Photo courtesy of Wikimedia Commons).
Image: Micrograph of an adult Caenorhabditis elegans (Photo courtesy of Wikimedia Commons).
Drug developers have identified a compound that in a worm model blocks the action of the type of toxic peptide plaques that characterize human neurodegenerative diseases such as Alzheimer's and Huntington's.

Aging manipulation is an emerging strategy aimed to postpone the manifestation of late-onset neurodegenerative disorders such as Alzheimer's (AD) and Huntington's diseases (HD) and to slow their progression once emerged. Investigators at the Hebrew University of Jerusalem (Israel) and their colleagues at the biopharmaceutical start-up company TyrNovo (Herzliya, Israel) had shown previously that reducing the activity of the insulin/IGF signaling cascade (IIS), a prominent aging-regulating pathway, protected nematode worms (Caenorhabditis elegans) from the toxicity of various aggregative proteins, including the AD-associated peptide, A-beta and the HD-linked peptide, polyQ40.

In the current study the investigators worked with an AD model based on a variant of C. elegans that expresses the highly aggregative, human AD-associated peptide, A-beta-42, in their body wall muscles. The expression of A-beta in these animals leads to a progressive paralysis within the worm population. The investigators treated the A-beta-42 worms with TyrNovo's novel compound NT219. NT219 possesses a unique mechanism, which leads to the elimination of IRS 1/2 and the long-term blockage of all signals they transmit.

Results published in the November 22, 2013, online edition of the journal Aging Cell revealed that NT219 mediated a long-lasting, highly efficient inhibition of the IIS signaling cascade by a dual mechanism. It reduced the autophosphorylation of the IGF1 receptor and directed the insulin receptor substrates 1 and 2 (IRS 1/2) for degradation. NT219 treatment promoted stress resistance and protected nematodes from the toxicity of AD- and HD-associated peptides without affecting the lifespan of the organism.

"The findings of the study reinforces the claim that blocking the signaling pathway of insulin and the growth hormone IGF1, a pathway known to be a central controller of the aging process in worms and mammals, can potentially be used as a treatment for degenerative brain diseases," said senior author Dr. Ehud Cohen, professor of biochemistry and molecular biology at the Hebrew University of Jerusalem. "The new findings are the first evidence that a pharmacological substance can effectively protect against toxicity of proteins associated with neurodegenerative diseases, through selective inhibition of the aging process."

The investigators have filed a patent application based on this study that includes the rights for use of NT219 as a therapeutic agent.

Related Links:

Hebrew University of Jerusalem



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Diagram illustrates the innovative process that could lead to more effective drugs against influenza infection (Photo courtesy of the Hebrew University of Jerusalem).

Researchers Show How the Influenza Virus Blocks Natural Killer Cell Recognition

A team of molecular virologists has described how the influenza virus evolved a defense mechanism to protect it from attack by the immune system's natural killer (NK) cells. The recognition of pathogen-infected... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Lab Technologies

view channel

Genome-Wide Mutation-Searching Computational Software Designed for Genomic Medicine

Analysis software cross-references a patient’s symptoms with his genome sequence to help physicians in the diagnosis of disease. This software was created by a team of scientists from A*STAR’s Genome Institute of Singapore (GIS), led by Dr. Pauline Ng. The research findings were published August 3, 2014, in the journal... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.